Posted in | News

The First Time Ever, Single Wall Carbon Nanotubes Complete REACH Registration

OCSiAl and its core product TUBALL™ single wall carbon nanotubes have opened a new substance in the EU's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation with the successful registration of TUBALL™ under the number 01-2120130006-75-0000. This registration proves that TUBALL™ single wall carbon nanotubes fully comply with REACH regulations, and are now available at industrial volumes.

OCSiAl is the world's first manufacturer of single wall carbon nanotubes (SWCNT) to complete REACH registration, taking the lead in raising the transparency of nanotube management worldwide and boosting their applications in a wide range of industries. REACH registration was successfully completed thanks to the collaboration between OCSiAl’s Health and Safety Department, Envigo and Intertek, which have jointly completed the comprehensive work involved in demonstrating compliance with the high standards and requirements of REACH.

Over the course of 6 months, highly qualified European experts conducted extensive research and testing on potentially hazardous properties of SWCNT. These tests have provided a view of the properties of SWCNT for the safe use of the substance.

The efforts of OCSiAl, Envigo and Intertek have resulted in the technical, and highly detailed, description of SWCNT, their nature and their potential risks, and in specifications on particular methods of risk management. This in-depth information will support the expansion of mass applications of SWCNT in various industries, including consumable products.

OCSiAl is the only company in the market that is capable of producing industrial-scale volumes of single wall carbon nanotubes. With its REACH registration, OCSiAl currently   commercializes 10 tonnes of single wall carbon nanotubes in Europe. OCSiAl’s global production capacity of TUBALL™ will reach 60 tonnes next year. REACH registration will support OCSiAl’s drive to further scale up its nanotube manufacturing volumes and to boost the company’s presence in the European market.

OCSiAl shares REACH’s goals and considers the completion of mandatory registration as one of the milestones in its path towards consistent transparency, providing the European market, and global community, with a more comprehensive understanding of nanotubes, their nature and safety.

According to OCSiAl’s EHS Lead Manager, Gunther Van Kerckhove

As part of OCSiAl’s commitment to product stewardship, the company also completed mandatory nanomaterials registration in France and Belgium in August 2016. Additionally, OCSiAl participates in the “EC4SafeNano” project, that is a part of the H2020 framework programme funded by the European Commission. Project aims to ensure the sustainable production and use of nanotechnologies as well as an understanding of the environmental, health and safety risks associated with nanotechnology and the resulting materials and products.

OCSiAl will continue to provide the global market with a thorough understanding of single wall carbon nanotubes, their nature, safety and unlimited potential for use in a wide range of industries and products.

We are very pleased to have been part of this successful collaboration – bringing our skills, expertise and comprehensive REACH testing capabilities to help OCSiAl meet all the requirements of REACH for TUBALL™. Fostering innovation through our regulatory research services is always a great plus for us. We are therefore delighted to have worked closely with InterTek and OCSiAl to enable the REACH registration of single wall carbon nanotubes – an industry first.

Adrian Hardy, Chief Executive Officer at Envigo

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.